In addition to alterations in major cell cycle regulators, CDK4/6 inhibitor resistance in breast cancer also involves various genomic alterations, with the RAS/MAPK and PI3K/AKT/mTOR pathways playing key roles. This evidence concerns the gene MTOR and breast carcinoma.